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Abstract 
Background: Epstein‑Barr virus (EBV) commonly infects the general population and has been associated with 
nasopharyngeal carcinoma (NPC), which has a high incidence in certain regions. This study aimed to address how EBV 
variations contribute to the risk of NPC.
Methods: Using logistic regression analysis and based on the sequence variations at EBV‑encoded RPMS1, a multi‑
stage association study was conducted to identify EBV variations associated with NPC risk. A protein degradation 
assay was performed to characterize the functional relevance of the RPMS1 variations.
Results: Based on EBV‑encoded RPMS1 variations, a single nucleotide polymorphism (SNP) in the EBV genome 
(locus 155391: G>A, named G155391A) was associated with NPC in 157 cases and 319 healthy controls from an NPC 
endemic region in South China [P < 0.001, odds ratio (OR) = 4.47, 95% confidence interval (CI) 2.71–7.37]. The results 
were further validated in three independent cohorts from the NPC endemic region (P < 0.001, OR = 5.20, 95% CI 
3.18–8.50 in 168 cases vs. 241 controls, and P < 0.001, OR = 5.27, 95% CI 4.06–6.85 in 726 cases vs. 880 controls) and 
a non‑endemic region (P < 0.001, OR = 7.52, 95% CI 3.69–15.32 in 58 cases vs. 612 controls). The combined analysis 
in 1109 cases and 2052 controls revealed that the SNP G155391A was strongly associated with NPC (Pcombined < 0.001, 
OR = 5.27, 95% CI 4.31–6.44). Moreover, the frequency of the SNP G155391A was associated with NPC incidence but 
was not associated with the incidences of other EBV‑related malignancies. Furthermore, the protein degradation assay 
showed that this SNP decreased the degradation of the oncogenic RPMS1 protein.
Conclusions: Our study identified an EBV variation specifically and significantly associated with a high risk of NPC. 
These findings provide insights into the pathogenesis of NPC and strategies for prevention.
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Background
Nasopharyngeal carcinoma (NPC) is a malignancy with 
a marked geographic distribution and ethnic tenden-
cies, occurring with high frequencies in South China, 
Southeast Asia, North Africa, and Alaska [1]. The etiol-
ogy of NPC is complex, involving multiple factors such as 
genetic susceptibility, Epstein-Barr virus (EBV) infection, 
and environmental factors [2–4]. The known association 
between EBV and NPC was mainly driven by findings 
that EBV-encoded molecules, some of which are poten-
tially oncogenic, were consistently observed in nearly all 
NPC tissues and that EBV serological markers, includ-
ing viral DNA load and antibodies against viral antigens, 
were associated with NPC diagnosis and prognosis [5–7].
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EBV infection is ubiquitous, affecting more than 95% 
of the worldwide population; EBV was also the first virus 
identified in a human tumor, i.e., Burkitt’s lymphoma. 
EBV has also been closely associated with Hodgkin’s lym-
phoma and some gastric cancers [8]. The incidences of 
these malignancies show remarkably different geographic 
distributions [9], which is paradoxical in comparison to 
the widespread infection with EBV. Moreover, sequence 
diversity in EBV genes has been demonstrated among the 
general population and in different tumor types [10, 11]. 
These results suggest the hypothesis that there might be 
some disease-specific EBV subtypes preferentially haz-
ardous to certain populations, making them more prone 
to certain specific diseases such as NPC.
A number of studies have reported attempts to 
identify NPC-specific EBV subtypes using restric-
tion fragment length polymorphism analysis and DNA 
sequencing based on the sequence variations of EBV 
genes. These genes were consistently observed in NPC 
tissues, including EBV nuclear antigens (EBNAs), latent 
membrane proteins (LMP1 and LMP2), and EBV-
encoded small nuclear RNAs (EBERs) [9, 10, 12]. EBV 
can be characterized as Type 1 (Type A) or Type 2 
(Type B) based on the sequence diversity of EBNA2 and 
EBNA3s [13, 14]. Type 1 EBV strains are more common 
worldwide, whereas Type 2 is equally prevalent in parts 
of Africa [15–17]. Based on an amino acid polymor-
phism at position 487 of EBNA-1, EBV has been clas-
sified into five strains: P-ala (B95-8 prototype), P-thr, 
V-val, V-leu, and V-pro [18–20]. V-val was detected 
almost exclusively in Chinese populations, whereas 
P-ala and P-thr were detected with a high prevalence in 
healthy individuals from both Chinese and non-Chinese 
populations [21, 22]. Based on the nucleotide sequence 
variations at the LMP1 C-terminus, EBV can be sepa-
rated into seven strains: China 1, China 2, Med, China 
3, Alaskan, NC, and B95-8 [23]. Among the Asian iso-
lates, China 1 and B95-8 were identified in healthy 
subjects, and China 1 and China 2 were found in NPC 
patients [23]. It has been reported that the Cantonese 
population is susceptible to the predominant China 1 
strain in the NPC endemic region in China [24]. These 
investigations suggested that there were relatively stable 
genomic variations in EBV and that different subtypes 
might exist in different geographic regions.
To further identify EBV variations linked closely to 
NPC risk, we conducted a pilot association analysis on 
several important EBV-encoded genes, including LMP1, 
EBNA1, and the BamHI-A rightward transcripts (BARTs) 
family, starting from NPC cases and healthy controls 
in the Cantonese population in South China. The most 
striking finding is that a single nucleotide polymorphism 
(SNP) in the EBV-encoded RPMS1 gene (locus 155391: 
G>A, named G155391A) is significantly associated with 
NPC incidence.
Previous studies have demonstrated that the BARTs 
family members are abnormally expressed in most NPC 
tissues and might contribute to NPC development [25, 
26]. RPMS1 encodes a major part of the mRNA of the 
BARTs family and is regularly transcribed in NPC tis-
sues [26, 27]. In particular, abundant RPMS1 mRNA was 
detected in NPC tissues and cell lines [28]. Considering 
the potential roles of RPMS1 in NPC oncogenesis [25, 27, 
29], we speculated that the sequence variation of RPMS1 
might contribute to the incidence variations of NPC 
among different geographic regions and ethnic groups. 
Therefore, we conducted a large-scale case–control study 
using a multistage design to identify the association 
between RPMS1 variations and NPC risk.
Methods
Subjects and samples
For the pilot study, 60 paired NPC cases and healthy con-
trols were recruited from Sun Yat-sen University Cancer 
Center (SYSUCC) between October 2005 and October 
2007. Throat washing (TW) samples were subjected 
to polymerase chain reaction (PCR) and direct DNA 
sequencing to screen for genomic variations exhibiting 
significant differences between the cases and controls.
The discovery stage involved 346 sporadic Canton-
ese NPC patients and 448 healthy subjects (Data_GD1), 
recruited from SYSUCC and the First Affiliated Hos-
pital of Sun Yat-sen University (1st AH-SYSU), Guang-
dong Province, an NPC endemic region in South China, 
between October 2005 and October 2007.
In the validation stage, three independent sample 
cohorts were collected from the NPC endemic and non-
endemic regions in China between October 2008 and 
June 2013. The first group consisted of 222 TW samples 
from sporadic NPC patients and 315 TW samples from 
healthy subjects from the SYSUCC and the 1st AH-
SYSU (Data_GD2). The second group consisted of 1065 
TW samples from sporadic NPC patients and 1161 TW 
samples from healthy subjects from the local community 
hospitals in Guangdong Province (Data_GD3). The third 
group consisted of 36 tumor biopsy (TB) samples and 66 
TW samples from NPC patients from the Affiliated Hos-
pital of Qingdao University (AH-QDU) and Shandong 
Province Cancer Center, in addition to 1543 TW sam-
ples from healthy subjects from the physical examination 
centers at local community hospitals in Shandong Prov-
ince, a NPC non-endemic region in North China (Data_
SD) (Table 1).
In the same period, additional TB samples from NPC 
patients were collected from NPC endemic regions in 
Asia, including 122 samples from SYSUCC, 30 samples 
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from the National Cancer Center of Singapore in Sin-
gapore, and 30 samples from the Chinese University of 
Hong Kong in Hong Kong. TB samples from patients with 
EBV-related malignancies were also collected, includ-
ing 10 samples of gastric carcinoma from AH-QDU and 
23 samples of lymphoma (Burkitt’s, NK/T cell, or Hodg-
kin’s) from SYSUCC. An additional 39 TW samples from 
patients with non-EBV-associated cancers were collected 
at SYSUCC. TW samples were also collected from healthy 
subjects in NPC non-endemic regions, including 83 sam-
ples from the Medical Examination Center of Henan 
Provincial Military Department in Henan Province, 100 
samples from the Beijing Centers for Diseases Control and 
Prevention in Beijing, 116 samples from the Third People’s 
Hospital of Datong in Shanxi Province, and 11 Caucasian 
samples from the Karolinska Institute in Sweden and the 
VU University Medical Center in Netherlands.
The selection criteria for patients were self-reported 
Chinese and newly diagnosed patients without any radio-
therapy, chemotherapy, or surgery. TW samples were col-
lected before any treatment. Basic information was also 
collected from the participants regarding age, gender, 
residential region, ethnicity, and familial history of NPC 
or other cancers. Healthy controls with no self-reported 
history of cancer were randomly recruited from physical 
examination centers in hospitals and were frequency-
matched to the cases by age (±5 years), gender, residen-
tial region, and ethnicity. This study was approved by the 
Human Ethics Committee at SYSUCC. Written informed 
consent was obtained from all the participants.
Isolation of DNA
Genomic DNA from TW samples was prepared using 
a conventional method. Briefly, the subjects rinsed 
their mouths with 15  mL of 0.9% saline for 10  s. Buc-
cal epithelial cells were pelleted by centrifugation at 
5000×g for 10  min. The cells were re-suspended and 
digested in a lysis buffer [10  mmol/L Tris·HCl with pH 
8.0, 100  mmol/L NaCl, 25  mmol/L ethylene diamine 
tetraacetic acid (EDTA), 0.5% Sarkosyl, and 0.1  mg/mL 
proteinase K] for 1–2  h at 55  °C. After treatment with 
RNase A, DNA was extracted from the cell lysate by add-
ing phenol/chloroform and then precipitated with etha-
nol, followed by dissolving in 50 μL of water. Genomic 
DNA from TB samples and cells was extracted using a 
commercial DNA extraction kit (DNeasy Blood & Tissue 
Kit, Qiagen, Valencia, CA, USA).
Sequence analysis and detection of SNP in RPMS1
In the pilot study, sequences of LMP1, EBNA1, and the 
BARTs family were detected by standard PCR and the 
direct Sanger sequencing method [22]. For RPMS1, only 
the second coding exon was considered (sequence length 
approximately 282  bp, covering 89.74% of the RPMS1 
coding region), as there was no variation in the first exon 
according to pairwise comparisons among GD1, AG876, 
and two wild-type EBV genomes (GenBank Accession 
No. AY961628, DQ279927, AJ507799, and NC_007605). 
Considering the low number of DNA copies of EBV in 
the TW samples, three rounds of nested PCR were sub-
sequently conducted to amplify the RPMS1 fragment as a 
way to increase the detection rate. Three primer pairs are 
listed in Table 2. In the first round, 2 μL of each genomic 
DNA served as the template, and PCR was performed in 
a 25-μL reaction system containing 0.25 μL of 20 μmol/L 
primer pair RPMS1-1/2, 2.0  mmol/L magnesium chlo-
ride, 0.2 mmol/L of each dNTP, and 0.625 unit of Go Taq 
DNA polymerase (Promega, Madison, WI, USA). In the 
Table 1 Characteristics of samples from nasopharyngeal carcinoma (NPC) cases and healthy controls from the four case–
control datasets






Data_GD1 Guangdong Oct 2005–Oct 2007 157/346 Sun Yat‑sen Univer‑
sity Cancer Center 
(SYSUCC)
319/448 The First Affiliated 




Data_GD2 Guangdong Oct 2008–Jun 2013 168/222 SYSUCC 241/315 1st AH‑SYSU NPC endemic
Data_GD3 Guangdong Oct 2008–Jun 2013 726/1065 Local hospitals 
in Guangdong 
province




Data_SD Shandong Oct 2008–Jun 2013 58/102 The Affiliated Hos‑
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second round, 2 μL of mixture from the first round PCR 
was used as the template with the primer pair RPMS1-3/4 
in a 25-μL reaction system. In the third round, the tem-
plate was 5 μL of mixture from the second round PCR, 
using the primer pair RPMS1-5/6, in a 50-μL reaction 
system. Raji DNA and water were used as positive and 
negative controls, respectively. The amplification proce-
dures for each round followed the manufacturer’s proto-
col. After PCR amplification, the nucleotide sequences of 
the PCR products were determined by Sanger sequenc-
ing (Fig. 1).
Cell culture
NP69 is an immortalized human nasopharyngeal epithe-
lial cell line originally presented by George Tsao at the 
University of Hong Kong and maintained at SYSUCC. 
NP69 cells were grown in defined Keratinocyte serum-
free medium supplemented with epidermal growth factor 
(EGF) (Invitrogen, Grand Island, NY, USA). The purity 
of NP69 cells was verified using short tandem repeat 
(STR) markers with the Goldeneye™20A STR kit (Peo-
plespot Co., Beijing, China) and an ABI 3100 analyzer 
(Thermo Fisher Scientific, Grand Island, NY, USA). Raji 
and C666-1 cells were maintained at our laboratory and 
cultured in RPMI-1640 medium supplemented with 10% 
fetal bovine serum (Gibco, Grand Island, NY, USA). 293T 
cells were maintained at our laboratory and grown in 
Dulbecco’s modified eagle medium supplemented with 
10% fetal bovine serum (Gibco). All cells were cultured in 
a humidified chamber with 5% CO2 at 37 °C.
Plasmids and generation of stable RPMS1 expression 
transfectants
Full-length cDNA of RPMS1 was obtained by PCR from 
the cDNA library derived from the EBV-positive NPC 
cell line C666-1 and then cloned into the pBABE-Puro 
retroviral vector (Cell Biolabs, San Diego, CA, USA). 
Mutations were introduced using the Quick-Change Site-
Directed Mutagenesis Kit (Stratagene, Santa Clara, CA, 
USA), and all mutations were verified by Sanger sequenc-
ing. The pBABE-Puro-RPMS1 (-Mut/-WT) expression 
vectors (constructed at our laboratory) and their corre-
sponding control vectors (Cell Biolabs) were packaged 
into the retrovirus generated by 293 T cells, followed by 
the infection of NP69 cells. The respective stable trans-
fectants in NP69 cells were selected against 1  μg/mL of 
puromycin.
Western blotting
Western blotting was performed as described previ-
ously [30]. Briefly, cells were lysed in mammalian cell 
lysis buffer, and proteins within the clarified lysates were 
resolved by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvi-
nylidene difluoride (PVDF) membranes for immunoblot-
ting against the corresponding antibody. The results were 
revealed using enhanced chemiluminescent (ECL) detec-
tion reagents (Beyotime Co., Shanghai, China). The rabbit 
polyclonal anti-RPMS1 antibody was from Proteintech 
Group Inc. (Wuhan, Hubei, China), and the human anti-
β-actin antibody was from Sigma-Aldrich Co. (St. Louis, 
MO, USA). A horseradish peroxidase (HRP)-conjugated 
anti-rabbit IgG antibody was used as the secondary anti-
body (Promega, Madison, WI, USA).
Statistical analysis
To test the association between EBV variations and NPC 
risk, odds ratios (ORs) and 95% confidence intervals 
(CIs) were estimated by unconditional logistic regres-
sion. Subjects with the EBV prototype (155391G) were 
treated as the reference. ORs were adjusted for gender 
and age, where both were taken as categorical covari-
ates (female or male; ≤35, 35–65, and >65 years). Fisher’s 
exact test was used to assess the frequency distribution 
of variables in two or more groups. The NPC risk associ-
ated with the affected EBV variations was characterized 
using the Cochran-Armitage trend test in the logistic 
Table 2 Primers used in the nested polymerase chain reac-
tion (PCR) and their sequences
EBV Epstein-Barr virus, EBNA1 EBV nuclear antigen 1, LMP1 latent membrane 
protein 1
a Coordinates relative to complete wild-type EBV genome (GenBank Accession 
No. NC_007605)
Primer EBV locusa Sequences (5′ → 3′) Note
EBNA1‑1 96,750–67 GGGAAGTCGTGAAAGAGC Outer primer
EBNA1‑2 97,479–96 GGTGGAAACCAGGGAGGC
EBNA1‑3 97,052–72 GGTTTGGAAAGCATCGT 
GGTC
Inner primer
EBNA1‑4 97,390–410 AACAAGGTCCTTAATC 
GCATC




LMP1‑CT‑3 167,755–72 CGGAACCAGAAGAACCCA Inner primer
LMP1‑CT‑4 168,244–61 TCCCGCACCCTCAACAAG
RPMS1‑1 155,087–107 GCTGGGTTGATGCTGT 
AGATG
1st round nested
RPMS1‑2 155,799–819 AGGGTCTGGACGTGGA 
GTTTG
RPMS1‑3 155,103–121 AGATGTGCCTGGCTCTGTC 2nd round nested
RPMS1‑4 155,543–63 CAATGACTTTGTCACCT 
TTGG
RPMS1‑5 155,199–220 AGAAGGCGTAGAGCATG 
TCCAG
3rd round nested
RPMS1‑6 155,460–81 GAGTACGACTGTGAGG 
TGGGCG
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regression analysis with adjustment for gender and age, 
where the variables of the EBV variations 155391G, 
155391G/A, and 155391A were coded by 0, 1, and 2 in 
the statistical model, respectively. All statistical analyses 
were performed using the R3.0.1 software (http://www.r-
project.org/). A P value of less than 0.05 was considered 
significant.
Results
Association between a SNP in the EBV genome and high 
risk of NPC
To identify genomic variations related to the NPC dis-
ease phenotype, in the pilot study, we sequenced the 
genomic regions of EBV-encoded genes, including 
LMP1, EBNA1, and the BARTs family, in 60 paired TW 
samples from NPC patients and healthy controls from 
a Cantonese population. Because, in NPC patients, 
multiple subtypes of EBV infection could be detected 
frequently in peripheral blood samples, and the EBV 
subtype detected in the normal nasopharyngeal tis-
sues was more similar to the subtype in the TB samples 
[16, 22], we chose to sequence DNA extracted from the 
TW samples. We found one SNP in RPMS1 (Loc155391 
G>A) with a significant difference between the cases 
and controls, and all the subsequent experiments on 
larger sample sizes were then focused on this genomic 
variation. In contrast, no significant associations with 
NPC risk were observed at the EBNA1 and LMP1 loci 
(Table 3).
In the discovery stage, TW samples from 157 NPC 
patients and 319 controls recruited from Guang-
dong Province were genotyped based on the 2nd exon 
sequence of RPMS1 (Data_GD1; Table 1). The SNP was 
recognized as Loc155391 (G>A) based on its coordinates 
mapping to the wild-type EBV genome (GenBank Acces-
sion No. NC_007605). Logistic regression analysis with 
adjustment for age and gender revealed a strong associa-
tion of the SNP at Loc155391 (named as G155391A) with 
Fig. 1 Validation of the RPMS1 single nucleotide polymorphism (SNP) G155391A by Sanger sequencing. a Representative RPMS1 155391G variant 
(wild type). b Representative RPMS1 155391A variant (mutant type). c Representative mixture type, individuals infected with both RPMS1 155391G 
and 155391A variants
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a high risk of NPC (P < 0.001, OR = 4.47, 95% CI 2.71–
7.37; Table 4).
Replication analyses
To replicate the association, Loc155391 was genotyped 
in two independent sample groups recruited from the 
same NPC endemic region, consisting of 168 NPC 
patients and 241 healthy controls from Data_GD2 and 
726 NPC patients and 880 healthy controls from Data_
GD3 (Table  1). Logistic regression analysis showed that 
SNP G155391A was significantly associated with a high 
NPC risk in both sample groups (Data_GD2: P < 0.001, 
OR  =  5.20, 95% CI  3.18–8.50; Data_GD3: P  <  0.001, 
OR  =  5.27, 95% CI  4.06–6.85; Table  4), indicating that 
the strong association was replicated in the two inde-
pendent sample groups. As further confirmation, logistic 
regression analysis for SNP G155391A was conducted in 
another sample group from Shandong Province in North 
China, which is a NPC non-endemic region, involving 
58 NPC patients and 612 healthy controls (Data_SD). 
The result revealed a consistently strong association 
between SNP G155391A and a high NPC risk (P < 0.001, 
OR = 7.52, 95% CI 3.69–15.32; Table 4), indicating that 
the association was further replicated. Meta-analysis of 
all the four samples with a total of 1109 NPC patients 
and 2052 healthy controls showed that SNP G155391A 
was associated with a high risk of NPC among all tested 
regions (P  <  0.001, OR =  5.27, 95% CI  4.31–6.44), and 
there was no evidence of heterogeneity among the 
included cohorts (P  =  0.71; Table  4). In addition, no 
other variations of RPMS1 were observed in any of the 
four sample groups.
Association of RPMS1 SNP G155391A and incidences 
of NPC and other malignancies
The frequencies of SNP G155391A were counted and 
compared among samples from Guangdong in South 
China, which is an NPC endemic region, as well as in 
North China and Europe, where NPC incidence is rela-
tively low. High frequencies of SNP G155391A were 
detected among the controls from Guangdong (48.4%), 
whereas the frequencies were significantly lower in North 
China (1.2%–8.0%) and Europe (0) (P  <  0.001; Table  5). 
Table 3 Association between  variations of  EBNA1 
and  LMP1 in  throat washing (TW) samples and  the risk 
of NPC in Guangdong population (pilot study)
Mix mixture of two or more EBV subtypes. Other abbreviations as in Tables 1 
and 2
Gene Subtype NPC  
[no. (%)]




155391G 8 (16.0) 29 (53.7)
155391G/A 0 4 (7.4)
155391A 42 (84.0) 21 (38.9)
EBNA1 0.677
V‑val 45 (90.0) 44 (84.6)
P‑ala 1 (2.0) 2 (3.8)
P‑thr 2 (4.0) 1 (1.9)
Mix 2 (4.0) 5 (9.6)
LMP1 0.080
China 1 27 (64.3) 39 (68.4)
China 2 4 (9.5) 2 (3.5)
B95.8 2 (4.8) 10 (17.5)
Mix 9 (21.4) 6 (10.5)
Table 4 Single nucleotide polymorphism (SNP) G155391A 
of RPMS1 and NPC risk
OR odds ratio, 95% CI 95% confidence interval, Inf Infinity. Other abbreviations as 
in Tables 1 and 2
a Datasets integrated by meta-analysis
† Ptrend Cochran-Armitage trend test in logistic regression analysis with 
adjustment for age and gender
‡ P heterogeneity test among the four datasets
EBV variant NPC Healthy subjects OR 95% CI P value
Data_GD1
 155391G 28 132 1
 G155391A 10 40 1.53 0.66–3.54 0.321
 155391A 119 147 4.47 2.71–7.37 <0.001
 P†trend <0.001
Data_GD2
 155391G 28 125 1
 G155391A 2 5 1.98 0.35–11.33 0.443
 155391A 138 111 5.20 3.18–8.50 <0.001
 P†trend <0.001
Data_GD3
 155391G 99 357 1
 G155391A 12 84 0.61 0.32–1.17 0.136
 155391A 615 439 5.27 4.06–6.85 <0.001
 P†trend <0.001
Data_SD
 155391G 40 560 1
 G155391A 0 18 0 0‑Inf 0.987
 155391A 18 34 7.52 3.69–15.32 <0.001
 P†trend <0.001
Overalla
 155391G 195 1174 1
 G155391A 24 147 0.92 0.56–1.51 0.746
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The increasing trend in the frequency of SNP G155391A 
in samples from regions with low to high NPC incidence 
was consistently observed in NPC patients, using either 
TW or TB samples (both P  <  0.001; Table  5). These 
results indicated that the frequency of SNP G155391A 
was associated with the NPC incidence and was sig-
nificantly increased in the tumor tissues. Moreover, as 
Burkitt’s lymphoma, Hodgkin’s lymphoma, NK/T-cell 
lymphoma, and some gastric cancers are well known as 
EBV-related malignancies, we compared the distribu-
tions of the RPMS1 SNP G155391A between other cancer 
samples and healthy controls. Interestingly, no evidence 
of association was observed between the RPMS1 SNP 
G155391A and the risks of tested cancers except for NPC 
(P  >  0.05; Table  6), suggesting that the association with 
the high-risk EBV variant might be specific to NPC.
Functional characterization of RPMS1 SNP G155391A
Endogenous RPMS1 protein was not detected, even 
though RPMS1 was implicated in NPC development. 
Although the BARTs contain many EBV-encoded micro-
RNA precursors [31], we failed to detect any alteration 
in the microRNAs predicted in the regions near RPMS1 
between the wild-type (155391G) and mutant (155391A) 
RPMS1 (data not shown). Thus, we suspected that the 
variation of G155391A from guanine (G) to adenine (A), 
leading to the amino acid change from Asp (D) to Asn 
(N), might be related to RPMS1 transcription or expres-
sion. Variations of the stable nasopharyngeal epithelial 
cell line NP69 integrating pBABE-Puro retroviral vec-
tor with mutant RPMS1 (155391A), wild-type RPMS1 
(155391G), and empty vector, respectively, were success-
fully constructed as revealed by Western blotting (Fig. 2a). 
After cycloheximide (CHX) treatment, RPMS1 protein 
degradation was clearly proceeding after 0.5  h in the 
NP69 cells with wild-type RPMS1 (155391G), whereas the 
degradation was hampered in the NP69 cells with mutant 
RPMS1 (155391A) (Fig. 2b). Moreover, the damped expo-
nential model indicated that the half-life for the mutant 
RPMS1 protein was significantly longer than that for the 
wild-type protein (3.2 vs. 0.6 h, P < 0.001; Fig. 2c), suggest-
ing that the SNP G155391A is functionally regulating the 
protein stability of RPMS1. In addition, when treated with 
the proteasome inhibitor MG132, a significant increase 
in RPMS1 protein expression was observed in the sta-
ble NP69 cell lines with overexpression of either wild-
type (155391G) or mutant RPMS1 (155391A) (Fig.  2d), 
suggesting that the RPMS1 protein might be degraded 
through the ubiquitin–proteasome pathway.
Discussion
In this multi-stage association study with a large sample 
size, we identified an EBV genomic sequence variation 
represented by RPMS1 SNP G155391A that was associ-
ated with a high risk of NPC. This association is much 
stronger than those of non-viral environmental factors, 
such as the consumption of salted fish and preserved 
food, with NPC risk [32–34]. The frequency of RPMS1 
SNP G155391A was significantly associated with the 
NPC incidence, and higher frequencies were observed 
in the NPC endemic areas, suggesting that RPMS1 SNP 
G155391A might explain the different incidences of NPC 
worldwide. RPMS1 SNP G155391A was enriched in NPC 
patients but was not associated with other malignancies; 
these results support the hypothesis that there is a highly 
oncogenic EBV subtype specifically leading to NPC risk.
Table 5 The frequencies of RPMS1 SNP G155391A in NPC cases and healthy controls from various world regions
TB tumor biopsy. Other abbreviations as in Tables 1 and 2
* Data combined in regions with low/high NPC incidence and probability calculated by Fisher’s exact test




NPC TB Shandong 36 23 0 13 36.1 Low
Guangdong 122 22 0 100 82.0 High
Hong Kong 30 2 0 28 93.3 High
Singapore 30 9 0 21 70.0 High <0.001
TW Shandong 22 17 0 5 22.7 Low
Guangdong 1051 155 24 872 83.0 High <0.001
Healthy subjects TW Europe 11 11 0 0 0.0 Low
Henan 83 81 1 1 1.2 Low
Beijing 100 91 1 8 8.0 Low
Shanxi 116 109 1 6 5.2 Low
Shandong 612 560 18 34 5.6 Low
Guangdong 1440 614 129 697 48.4 High <0.001
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Table 6 Association of RPMS1 SNP G155391A with the risk of NPC and other malignancies
NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, EBVaGC EBV-associated gastric carcinoma. Other abbreviations as in Tables 1 and 2
a Healthy subjects from the discovery and replication stages were combined
# EBV-free tumors included lung cancer, liver cancer, colorectal cancer, and pancreatic cancer, among others, which were not associated with EBV
‡ NHL included Burkitt’s and NK/T-cell lymphomas
† The frequency of RPMS1 SNP G155391A in healthy subjects from the same region was considered as a reference, with Fisher’s exact test performed
˄ Lymphoma was considered as a reference
˅ EBVaGC was considered as a reference
Region Sample Source 155391G & 155391G/A 155391A OR P
Guangdong Healthy subjectsa TW 743 697 1
EBV‑free tumor# TW 24 15 0.67† 0.257
NHL‡ TB 8 5 0.67† 0.582
HL TB 7 3 0.46† 0.345
Lymphoma (NHL + HL) TB 15 8 0.57† 0.213
NPC TB 22 100 8.35˄ <0.001
Shandong Healthy subjectsa TW 578 34 1
EBVaGC TB 10 0 0† 1.000




NP69                    WT         Mut          Vec           WT         Mut         Vec
MG132 (1 hour)       - - - +             +              +
NP69-WT 








Fig. 2 Effect of the RPMS1 SNP G155391A on the degradation of RPMS1 protein. a Western blotting analysis showing the expression levels of 
RPMS1 in NP69 cell lines established with the stable integration of the pBABE‑Puro retroviral vector of mutant RPMS1 (‑Mut), wild‑type RPMS1 (‑WT), 
and control vector (‑Vec), respectively. b Western blotting results showing the degradation of RPMS1 protein. NP69 cells with stable overexpression 
of mutant RPMS1 (‑Mut) or wild‑type RPMS1 (‑WT) were incubated with 20 μg/mL cycloheximide (CHX) for the indicated periods of time (0, 0.5, 
1.0, 1.5, 2.0, and 2.5 h). c Fitted curves of the degradation of the RPMS1 protein of EBV variations under the damped exponential model. d Western 
blotting results showing the RPMS1 protein expression in NP69 cells with stable overexpression of mutant RPMS1 (‑Mut) or wild‑type RPMS1 (‑WT), 
treated with or without 10 μmol/L MG132 for 1 h
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The identification of the high-risk RPMS1 SNP 
G155391A for NPC emphasizes that the contribution of 
EBV strain variation to virus-associated malignancies 
should not be ignored. A similar scenario is the associa-
tion of human papillomavirus (HPV) with cervical carci-
nomas, in which highly oncogenic HPV subtypes 16, 18, 
and 45 are the predominant contributors to the disease 
among more than 150 HPV subtypes [35, 36]. Therefore, 
HPV vaccine programs have shown promising popula-
tion-level impacts, and the screening of HPV subtypes is 
important for the early detection of cervical carcinomas 
[37]. Indeed, serological EBV markers are potentially use-
ful for screening individuals with a high risk of NPC in 
multiplex families [38]. The identification of the high-risk 
RPMS1 SNP G155391A suggests that we should consider 
the contribution of EBV variations to the applications of 
serological EBV markers, such as DNA in NPC monitor-
ing and prognostication [39]. With further investigation 
of other high-risk EBV variations, if any, we might be able 
to develop effective vaccines against high-risk EBV sub-
types to promote NPC prevention.
RPMS1 is a unique gene belonging to the EBV BARTs 
family, which is abnormally expressed in most NPC tis-
sues at the RNA level and might contribute to NPC 
development [25, 26]. No endogenous RPMS1 protein 
has been reported in cultured NPC cells or NPC tumor 
biopsies [40], and thus, we suspected that RPMS1 might 
be translated into protein at very low levels, or else that 
the RPMS1 protein was degraded very rapidly. Indeed, 
we found that the RPMS1 variations defined by 155391A 
and 155391G are functionally relevant to the stability of 
RPMS1 protein overexpressed in  vitro (Fig.  2). Com-
pared with the low-risk 155391G, the high-risk 155391A 
resulted in a longer half-life of RPMS1 protein, as shown 
in the protein degradation assays. With oncogenic capac-
ity, RPMS1 has been shown to interact with the Notch 
intracellular domain and regulate the downstream path-
way to promote cell differentiation and proliferation [41]. 
A recent genome sequencing study of NPC revealed accu-
mulated mutations in the genes involved in the Notch 
pathway, including NOTCH1, NOTCH2, and NOTCH3 
[42], suggesting that the dysregulation of the Notch path-
way might be an important driving event in NPC. These 
results further suggest that the interaction between EBV-
encoded RPMS1 and the host Notch pathway might be a 
significant process during NPC development and that the 
high-risk 155391A, leading to a longer half-life of RPMS1 
protein, may exhibit stronger carcinogenesis potential.
Conclusions
We discovered a high-risk EBV SNP for NPC, which 
suggests the existence of disease-related EBV sub-
types. Moreover, our findings indicate that different 
distributions of EBV subtypes in different geographic 
regions and ethnic groups might be among the rea-
sons for the differences in NPC incidence worldwide. 
Therefore, our results provide new insights for screen-
ing populations at a high risk of NPC and strategies for 
EBV vaccine development in the future. We acknowledge 
that further studies with larger sample sizes, more ethnic 
groups, and more geographic regions are needed to rep-
licate our findings and rule out the confounding effects 
of population and the source of EBV, as the RPMS1 SNP 
G155391A had much higher frequency in the Guangdong 
area based on TW samples. Certainly, more efforts are 
required to analyze the whole genome sequence of EBV 
to define haplotypes, instead of a single SNP, for genotyp-
ing the virus detected in healthy subjects or patients with 
different disorders and different ethnicities.
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